Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights Aug 07, 2017 4:05pm EDT
Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference Aug 02, 2017 8:00am EDT
Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) Jul 31, 2017 8:10am EDT
Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) May 10, 2017 5:00pm EDT
Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team May 10, 2017 8:00am EDT
Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights May 04, 2017 4:15pm EDT
Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) Apr 21, 2017 8:00am EDT
Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017 Apr 20, 2017 4:20pm EDT
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer Apr 03, 2017 8:00am EDT
